V.K. Beloglazov¹, V.S. Levchenko¹, S.V. Gamayunov¹, ², G.A. Raskin³, V.M. Nechushkina², ⁴
1Nizhny Novgorod Regional Clinical Oncology Dispensary, Nizhny Novgorod
2Privolzhsky Research Medical University, Nizhny Novgorod
3Medical Institute named after Berezin Sergey (MIBS), Saint Petersburg
4ANO “Scientific and Educational Center of EAFD “Eurasian Oncology Program”, Moscow
Beloglazov V.K. — oncologist of the 7th Oncology Department of Oncogynecology
190, Rodionova St., Nizhny Novgorod 603000, Russian Federation, tel.: +7-930-818-40-70, e-mail: beloglazov999@list.ru, ORCID ID: 0000-0001-6866-3917
Abstract. Endometrial cancer is one of the most frequently diagnosed malignant tumors of the female reproductive organs both in the Russian Federation and in Europe, Asia, and North America. The most common histological type is endometrioid adenocarcinoma, accounting for about 80–85% of newly diagnosed cases.
In 2013, a comprehensive genomic analysis conducted by The Cancer Genome Atlas (TCGA) identified four molecular subtypes of endometrial cancer: POLE-ultramutated, MMR-deficient (dMMR), p53-mutant, and with no specific molecular profile (NSMP). This review focuses on analyzing the main characteristics of TCGA molecular subtypes and their prognostic and therapeutic significance.
Key words: endometrial cancer, molecular classification, prognosis, diagnostics, risk assessment